Aclaris Therapeutics Inc

8AT

Company Profile

  • Business description

    Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

  • Contact

    701 Lee Road
    Suite 103
    WaynePA19087
    USA

    T: +1 484 324-7933

    E: [email protected]

    https://www.aclaristx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    64

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,579.9050.100.59%
CAC 407,886.6933.220.42%
DAX 4023,767.4371.840.30%
Dow JONES (US)42,654.74331.990.78%
FTSE 1008,684.5650.810.59%
HKSE23,345.05108.11-0.46%
NASDAQ19,211.1098.780.52%
Nikkei 22537,753.721.79-0.00%
NZX 50 Index12,786.7994.03-0.73%
S&P 5005,958.3841.450.70%
S&P/ASX 2008,343.7046.200.56%
SSE Composite Index3,367.4613.36-0.40%

Market Movers